Although US stocks ended slightly higher on Friday, there was some notable insider trading.

When insiders buy stock, it shows they have confidence in the company’s prospects or that they see the stock as a bargain. Either way, it signals an opportunity to go long the stock. Insider buying should not be taken as the sole indicator of an investment or trading decision. At best, it can convince a purchase decision.

Below is a look at some notable recent insider purchases. For more information, see Benzinga insider trading Platform.

destiny therapy

• The trade: Fate Therapeutics, Inc. FATE Director Jeremy Green acquired a total of 276,639 shares an average price of $6.17. The purchase of these shares cost around 1.71 million US dollars.
• What’s up: Fate Therapeutics reported a smaller-than-expected loss in the fourth quarter.
• What Fate Therapeutics does: Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune diseases.

BCB Bancorp

• The trade: BCB Bancorp, Inc. BCBP Director James G. Rizzo purchased a total of 2,000 shares an average price of $11.21. Acquisition of these shares cost about 22.42 thousand US dollars.
• What’s up: BCB Bancorp published weak Q1 results.
• What BCB Bancorp does: BCB Bancorp Inc is a bank holding company.

Don’t forget to check out ours premarket coverage here

AMREP

• The trade: AMREP Corporation AXR Director Edward B. Cloues, II bought a total of 1,000 shares at an average price of $15.00. It cost around $15,000 to acquire these shares.
• What’s up: Amrep posted an increase in Q3 EPS.
• What AMREP does: Amrep Corp, through its subsidiaries, is engaged in the real estate business. Its activities include real estate sales and leasing activities, which involve the obtaining of permits and the sale of developed and undeveloped land to developers, commercial…